Beige fat is dispensable for the metabolic benefits associated with myostatin deletion.
Adipocytes, Beige
/ metabolism
Adipose Tissue
/ metabolism
Adipose Tissue, Beige
/ metabolism
Animals
Body Temperature Regulation
/ physiology
DNA-Binding Proteins
/ genetics
Fatty Liver
/ metabolism
Female
Glucose
/ metabolism
Glucose Intolerance
/ metabolism
Insulin Resistance
/ physiology
Male
Mice
Mice, Inbred C57BL
Mice, Knockout
Muscle, Skeletal
/ metabolism
Myostatin
/ genetics
Obesity
/ metabolism
Thermogenesis
Transcription Factors
/ genetics
Beige adipocytes
Hepatic steatosis
Insulin resistance
Metabolic dysfunction
Muscle hypertrophy
Obesity
Journal
Molecular metabolism
ISSN: 2212-8778
Titre abrégé: Mol Metab
Pays: Germany
ID NLM: 101605730
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
08
09
2020
revised:
08
11
2020
accepted:
13
11
2020
pubmed:
22
11
2020
medline:
31
8
2021
entrez:
21
11
2020
Statut:
ppublish
Résumé
Increasing muscle mass and activating beige fat both have great potential for ameliorating obesity and its comorbidities. Myostatin null mice have increased skeletal muscle mass and are protected from obesity and its sequelae. Deletion of myostatin has also been suggested to result in the activation of beige adipocytes, thermogenic fat cells with anti-obesity and anti-diabetes properties. It is not known whether beige fat activation contributes to the protection from obesity in myostatin null mice. To investigate the role of beige fat activation in the metabolic benefits associated with myostatin deletion, we crossed myostatin null mice to adipocyte-specific PRDM16 knockout mice. We analyzed this new mouse model using molecular profiling, whole mount three-dimensional tissue imaging, tissue respiration, and glucose and insulin tolerance tests in models of diet-induced obesity. Here, we report that PRDM16 is required for the activation of beige fat in the absence of myostatin. However, we show in both male and female mice that beige fat activation is dispensable for the protection from obesity, glucose intolerance, insulin resistance, and hepatic steatosis mediated by myostatin deletion. These findings demonstrate that increasing muscle mass can compensate for the inactivation of beige fat and raise the possibility of targeting muscle mass as a therapeutic approach to offset the deleterious effects of adipose tissue dysfunction in obesity and metabolic syndrome.
Identifiants
pubmed: 33220490
pii: S2212-8778(20)30194-0
doi: 10.1016/j.molmet.2020.101120
pmc: PMC7736974
pii:
doi:
Substances chimiques
DNA-Binding Proteins
0
Myostatin
0
Prdm16 protein, mouse
0
Transcription Factors
0
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
101120Subventions
Organisme : NIDDK NIH HHS
ID : P30 DK020541
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK120649
Pays : United States
Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier GmbH.. All rights reserved.
Références
Cell Metab. 2008 Feb;7(2):159-72
pubmed: 18249175
Nature. 1997 May 1;387(6628):83-90
pubmed: 9139826
J Clin Endocrinol Metab. 2011 Sep;96(9):2898-903
pubmed: 21778224
Int J Obes (Lond). 2017 Jan;41(1):137-148
pubmed: 27297797
J Appl Physiol (1985). 2005 Sep;99(3):1220-5
pubmed: 15860689
Nat Med. 2015 Apr;21(4):389-94
pubmed: 25774848
Diabetologia. 2012 Jan;55(1):183-93
pubmed: 21927895
Int J Obes (Lond). 2006 May;30(5):868-70
pubmed: 16404405
Int J Obes (Lond). 2009 Nov;33(11):1265-73
pubmed: 19668253
Cell Metab. 2014 Apr 1;19(4):593-604
pubmed: 24703692
Lancet. 2017 Dec 16;390(10113):2627-2642
pubmed: 29029897
N Engl J Med. 2009 Apr 9;360(15):1518-25
pubmed: 19357407
Cell Metab. 2018 Jan 9;27(1):226-236.e3
pubmed: 29320703
Int J Obes (Lond). 2020 Sep;44(9):1851-1858
pubmed: 32404950
FASEB J. 2013 May;27(5):1981-9
pubmed: 23362117
N Engl J Med. 2019 Dec 19;381(25):2440-2450
pubmed: 31851800
Muscle Nerve. 2017 Apr;55(4):458-464
pubmed: 27462804
Cell. 2016 Mar 24;165(1):125-138
pubmed: 27015310
J Clin Invest. 2002 Mar;109(5):595-601
pubmed: 11877467
J Endocrinol Invest. 2002 Nov;25(10):823-35
pubmed: 12508945
Endocrinology. 2012 Jul;153(7):3133-46
pubmed: 22549226
N Engl J Med. 2009 Apr 9;360(15):1500-8
pubmed: 19357405
Lancet. 2016 Aug 20;388(10046):776-86
pubmed: 27423262
J Clin Invest. 2013 Aug;123(8):3404-8
pubmed: 23867622
J Clin Invest. 2011 Jan;121(1):96-105
pubmed: 21123942
J Clin Invest. 1990 Nov;86(5):1423-7
pubmed: 2243122
Cell Metab. 2015 Jan 6;21(1):33-8
pubmed: 25565203
Eur J Clin Nutr. 2014 Sep;68(9):1001-7
pubmed: 24961545
Diabetes. 2009 May;58(5):1133-43
pubmed: 19208906
N Engl J Med. 2009 Apr 9;360(15):1509-17
pubmed: 19357406
Nature. 2008 Aug 21;454(7207):961-7
pubmed: 18719582
Cell. 2014 Jan 16;156(1-2):304-16
pubmed: 24439384
Arterioscler Thromb Vasc Biol. 2008 Jun;28(6):1039-49
pubmed: 18356555
Mol Cell Biol. 2012 Jul;32(14):2871-9
pubmed: 22586266